Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Rohan Savoor"'
Autor:
Lijie Zhai, Erik Ladomersky, Kristen L. Lauing, Meijing Wu, Denise M. Scholtens, Rohan Savoor, Bin Zhang, Jennifer D. Wu, Craig Horbinski, Rimas V. Lukas, David C. Binder, Derek A. Wainwright
Publikováno v:
OncoImmunology, Vol 8, Iss 3 (2019)
Preclinical modeling and gene expression analyses have yielded distinct observations for the role of immune checkpoint, IDO1, in glioblastoma (GBM). Accordingly, our recent work differs with Garg et al. (2017) with respect to IDO1 among preclinical a
Externí odkaz:
https://doaj.org/article/4f3c72e704db4a8ca010fd1b67d431de
Autor:
Nader S. Dahdaleh, Sean Sachdev, Maryanne H. Marymont, Rimas V. Lukas, Zachary A. Smith, Timothy L. Sita, Aruna Ganju, John A. Kalapurakal, Tyler R. Koski, Tim J. Kruser, Irene Helenowski, Rohan Savoor
Publikováno v:
Journal of Neuro-Oncology. 151:241-247
Spinal ependymomas represent the most common primary intramedullary tumors for which optimal management remains undefined. When possible, gross total resection (GTR) is often the mainstay of treatment, with consideration of radiotherapy (RT) in cases
Autor:
Timothy L. Sita, Mahesh Gopalakrishnan, Michael K. Rooney, Alexander Ho, Rohan Savoor, Adam M. Sonabend, Matthew C. Tate, James P. Chandler, Maciej S. Lesniak, Tim J. Kruser, John A. Kalapurakal, Sean Sachdev
Publikováno v:
World neurosurgery. 165
Gamma Knife (GK) stereotactic radiosurgery (SRS) is increasingly used as an initial treatment for patients with 10 or more brain metastases. However, the clinical and dosimetric consequences of this practice are not well established.We performed a si
Autor:
Mahesh Gopalakrishnan, Tim J. Kruser, Michael K. Rooney, Adam M. Sonabend, Maciej S. Lesniak, James P. Chandler, Matthew C. Tate, Alexander Ho, Sean Sachdev, Rohan Savoor, John A. Kalapurakal, Timothy L. Sita
Purpose:Gamma Knife (GK) stereotactic radiosurgery (SRS) is increasingly used as an initial treatment for patients with ten or more brain metastases (BM). However, the clinical and dosimetric consequences of this practice are not well established.Met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df2255e01561b1d9656c552f909da7d7
https://doi.org/10.21203/rs.3.rs-887481/v1
https://doi.org/10.21203/rs.3.rs-887481/v1
Autor:
Clifford G. Robinson, Michael C. Roach, Tim J. Kruser, Timothy L. Sita, Michelle S. Gentile, Rohan Savoor, Nisha Mohindra, Jeffrey D. Bradley, Pamela Samson, Saiama N. Waqar, Comron Hassanzadeh
Publikováno v:
J Thorac Dis
Background Consolidation durvalumab improved overall survival (OS) in locally advanced non-small cell lung cancer (LA-NSCLC) treated with chemoradiotherapy (CRT) in the PACIFIC trial; however, pneumonitis was increased with durvalumab. We sought to e
Autor:
Rohan, Savoor, Timothy L, Sita, Nader S, Dahdaleh, Irene, Helenowski, John A, Kalapurakal, Maryanne H, Marymont, Rimas, Lukas, Timothy J, Kruser, Zachary A, Smith, Tyler, Koski, Aruna, Ganju, Sean, Sachdev
Publikováno v:
Journal of neuro-oncology. 151(2)
Spinal ependymomas represent the most common primary intramedullary tumors for which optimal management remains undefined. When possible, gross total resection (GTR) is often the mainstay of treatment, with consideration of radiotherapy (RT) in cases
Autor:
Sean Sachdev, Michael Drumm, Craig Horbinski, Tim J. Kruser, Rohan Savoor, Nikhil Rammohan, Irene Helenowski, E.T. Benishay, Amishi Bajaj
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:e587
Purpose/Objective(s) Recent autopsy data from patients with glioblastoma (GBM) has demonstrated that pronounced brainstem infiltration is now a common pattern of disease progression near the end of life. The present study evaluated the association of
Autor:
Jun Qian, Erik Ladomersky, Derek A. Wainwright, Rohan Savoor, Lijie Zhai, Sebastian Otto-Meyer, April Bell, Kristen L. Lauing
Publikováno v:
Neuro Oncol
INTRODUCTION Immunotherapy has failed to improve glioblastoma (GBM) patient survival in all phase III clinical trials to-date. We recently discovered that a combination immunotherapeutic approach that simultaneously administers radiation (RT), anti-P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::205e197ff232c7c0b73941c6257fa93d
https://europepmc.org/articles/PMC6846934/
https://europepmc.org/articles/PMC6846934/
Autor:
Kristen L. Lauing, Derek A. Wainwright, Erik Ladomersky, Jun Qian, Sebastian Otto-Meyer, Rohan Savoor, Lijie Zhai
Publikováno v:
Neuro Oncol
Immunotherapy has failed to improve the overall survival (OS) of adults with GBM in all phase III clinical trials to-date. Somewhat less appreciated is that, de novo GBM is a disease associated with a median age of diagnosis at 64 years old. Because
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe978399449309dfb06cb0cb34342f54
https://europepmc.org/articles/PMC6847513/
https://europepmc.org/articles/PMC6847513/
Autor:
Derek A. Wainwright, Sebastian Otto-Meyer, Erik Ladomersky, Kristen L. Lauing, Lijie Zhai, Alicia Lenzen, Rohan Savoor, Rimas V. Lukas
INTRODUCTION: Glioblastoma (GBM) is an aggressive, incurable, primary brain tumor with a median survival of 15–20 months. High intratumoral expression of indoleamine 2,3-dioxygenase 1 (IDO1), an immunosuppressive enzyme that metabolizes tryptophan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a52593d70acf30c81834fcd8dcd07f9
https://europepmc.org/articles/PMC6217352/
https://europepmc.org/articles/PMC6217352/